Applied DNA and the Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications
September 08 2022 - 10:00AM
Business Wire
- Agreement Leverages Company’s Ability for
Intramuscular Delivery of LNP-Encapsulated LinearDNA-based
Therapies for Veterinary Therapeutic and Prophylactic Applications
-
Applied DNA Sciences, Inc. (NASDAQ: APDN) (‘Applied DNA’ or the
“Company”), a leader in polymerase chain reaction ("PCR")-based
technologies, and the Cornell University College of Veterinary
Medicine (“CUCVM”) announced the signing of a research agreement
(the “Agreement”) to advance LinearDNA™-based vaccine research and
discovery for animal diseases with agricultural biosecurity
implications. Primarily, the Agreement seeks to combine LinearDNA
as a platform for rapid drug development with CUCVM’s expertise in
viral vector design to advance a differentiated approach to animal
vaccine development for infectious diseases.
The Agreement builds on the strong, existing collaboration
between Applied DNA’s biotherapeutics subsidiary, LineaRx, and Dr.
Diego Diel, D.V.M, M.S., PhD., Associate Professor of Virology at
the Cornell University College of Veterinary Medicine’s Department
of Population Medicine and Diagnostics. Dr. Diel is the lead
investigator for veterinary clinical trials sponsored by the
Company for the LinearDNA-based COVID-19 vaccine candidate and
other therapeutic candidates in the Company’s pipeline.
Recently, Applied DNA announced the successful administration
and expression of a lipid nanoparticle-encapsulated (LNP) LinearDNA
construct in mice via routine intramuscular (IM) injection. Based
on this positive data, the Company is currently advancing several
LNP LinearDNA vaccine designs that will be utilized in upcoming
preclinical animal studies. Data generated by these preclinical
animal studies will advance the LinearDNA platform toward the
commercialization of LNP-LinearDNA vaccines for both prophylactic
and therapeutic applications and will inform the final design of
the Company’s LNP-LinearDNA canine cancer vaccine candidate that is
currently slated to begin an initial clinical trial during 1H
calendar 2023.
“The Agreement is an opportunity to expand our work with Dr.
Diel and his talented team to accelerate the application of the
LinearDNA platform to the animal health market,” stated Dr. James A
Hayward, president and CEO of Applied DNA and LineaRx. “Veterinary
DNA vaccines present an attractive opportunity for us, and these
animal studies should generate additional key validation data for
our platform relevant to veterinary health. There is a continuing
need for better veterinary therapies and we believe an
LNP-LinearDNA product has the strong potential to offer enhanced
ease of administration and improved clinical outcomes.”
Dr. Diel said, “Vaccinology research and clinical trials are
crucial to developing new prevention strategies that could have
transformative applications in animal health. This partnership will
help to advance research and development of novel vaccine
candidates for emerging infectious diseases in ways that can
benefit us all, including human and animal patients.”
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing
technologies to produce and detect deoxyribonucleic acid (“DNA”).
Using PCR to enable both the production and detection of DNA, we
operate in three primary business markets: (i) the manufacture of
DNA for use in nucleic acid-based therapeutics; (ii) the detection
of DNA in molecular diagnostics testing services; and (iii) the
manufacture and detection of DNA for industrial supply chain
security services.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under the ticker
symbol ‘APDN,’ and its publicly traded warrants are listed on OTC
under the ticker symbol ‘APPDW.’
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
"forward-looking" in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA's future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to, its history of
net losses, limited financial resources, limited market acceptance,
the uncertainties inherent in research and development, future
clinical data and analysis, including whether any of Applied DNA's
or its partner's therapeutic candidates will advance further in the
preclinical research or clinical trial process, including receiving
clearance from the U.S. Food and Drug Administration (FDA), United
State Department of Agriculture (USDA) or equivalent foreign
regulatory agencies to conduct clinical trials and whether and
when, if at all, they will receive final or conditional approval
from the FDA, USDA or equivalent foreign regulatory agencies, the
unknown outcome of any applications or requests to FDA, USDA or
equivalent foreign regulatory agencies, whether results from
preclinical studies will be predictive of the results of later
preclinical studies and clinical trials, the unknown ability to
manufacture the therapeutic grade DNA in large quantities, the fact
that there has never been a commercial drug product utilizing
PCR-produced DNA technology approved for therapeutic use, and
various other factors detailed from time to time in Applied DNA's
SEC reports and filings, including our Annual Report on Form 10-K
filed on December 9, 2021, its Quarterly Report on Form 10-Q filed
on February 10, 2022 and May 12, 2022, and August 11, 2022, and
other reports it files with the SEC, which are available at
www.sec.gov. Applied DNA undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events, or circumstances after the date hereof or to reflect the
occurrence of unanticipated events, unless otherwise required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220908005487/en/
Investor Relations: Sanjay M. Hurry, 917-733-5573,
sanjay.hurry@adnas.com Program: Brian Viscount,
631-240-8877, brian.viscount@adnas.com Web: www.adnas.com
Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024